Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast with teleconference, Q2'24

By Inderes7/16/2024, 12:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:00 - 00:00

Go ahead.

Fredrik Tiberg
00:01 - 02:41

Thank you so much. And good day, everyone. Thank you for joining. It's a pleasure to report on Camurus's second quarter earnings today. Before starting, please note our forward-looking statements. So the agenda for today's call will be a short summary of second quarter highlights, followed by a review of financial performance. We will then move to commercial and R&D pipeline updates and finish off with a Q&A, and with me in the call today. Like previously, it's John Garay Alonso, our CFO, and Richard Jameson, Chief Commercial Officer. So we had a solid second quarter with strong operational performance across the business. This resulted in positive financial development. Our revenues in the quarter were 445 million SEK, representing a 46% year-on-year growth, excluding a one-time revenue from the US approval of Buvidal in 2023. Profit before tax in the quarter was 104 million SEK and 201 million for the first half of the year. Our cash position at the end of the quarter grew to 2.6 billion SEK. In the company, commercially, we continued advancing our global leading position in the opioid dependence treatment area. Buvidal sales grew to 400 million SEK in the quarter. In the US, the adoption of Buvidal continued to be strong and royalties increased by 73% quarter-on-quarter to 45 million SEK. In R&D, we progressed our pipeline according to plan. EMA issued an acceptance for review of our market authorization application for CAM2029. In acromegaly, and in parallel, FDA review of the corresponding New Drug Application for CAM2029 advanced towards the PDUFA date in October. On the clinical side, the core phase of the Nova two study was completed. <www /> I'll present some of the results later here. With final results announced yesterday, we also completed our preclinical studies for once-monthly semaglutide and are preparing for a planned start of clinical study by the camera. So overall, we had a very productive second quarter with significant progress across our business. And, with this positive initial remark, I'll leave the word to John for a financial review.

John Garay Alonso
02:43 - 07:08

Thanks a lot, Fredrik, and good afternoon, everyone. During the quarter, Camurus continued its development, delivering strong profitability and remains on track to achieve our 2027 vision. I would like to share now key highlights of our financial performance this quarter. At the end of the quarter, Camurus achieved 445 million total revenue compared to 674 million SEK in the same period last year. Excluding 369 million one-time revenues driven by FDA approval in 2023. Company revenues grew by 139 million, delivering a growth of 46% versus the same period last year. Mobile sales reached 400 million SEK, growing 31% compared to the previous year and 10% compared to the prior quarter. The depreciation of the Swedish krona has positively impacted reported figures by 3% on a year-on-year basis and 4% versus the prior quarter. Sales in the US represented a 45 million royalty income in the quarter, representing a 19 million SEK improvement compared to the previous quarter. Company profit before tax was $104 million, achieving an earnings per share after dilution of 1.25 Swedish kronor, equivalent to a profit after tax of $74 million in the quarter. Moving to the next slide, we can see the main components of our profit before tax. Company gross margin reached 92.9% in the quarter. Excluding one-time revenues impact, it represents an improvement of 233 basis points versus the same period in the prior year, driven by three major factors. Firstly, supply chain efficiencies driven by higher volumes and scale-up represented 171 basis points. Secondly, 83 basis points are driven by solid royalty. And thirdly, it represented a negative impact of 21 basis points. Total opex reached 331 million, representing a 23% increase versus the same period last year, driven by the following factors. Marketing and distribution investment to support market penetration in owned territories. Expansion of Babylon into new markets and the U.S. Operations grew 39% to $131 million. Administrative expenses aligned with corporate evolution to substantiate company development grew 97% versus the same period last year to $24,000,000. R&D investment reached 174 million SEK, growing 8% versus the same period last year, driven by progress in our preclinical and clinical pipeline. Company profit before tax reached $104,000,000, excluding one-time revenues. It represents an improvement of 92 million SEK, increasing by 763% compared to the same period in the previous year. Company cash position at quarter-end was 2.6 billion SEK. Camurus improved its cash position by 293 million in the quarter, driven by the following four factors. Firstly, company operations generated $155 million. Secondly, working capital increased by 56 million, driven primarily by growth in receivables. Thirdly, financing activities mainly driven by the exercise of stock option programs by our employees delivered $196,000,006. And finally, the company invested $2,000,002 in technological activities as of the end of the quarter. Camurus has no debt. All in all, Camurus closed the second quarter with a strong operational performance and solid financial position. Camurus reiterates its 2024 financial outlook and expects to finalize in the mid to high end of current guidance. Having said that, I would like to pass the word to Richard Jameson. Thank you everyone for your attention.

Richard Jameson
07:09 - 10:49

Thank you, John. So as usual, I will start with an update on Camurus, markets, and then progress to the progress with Brixadi in the US. Starting with the markets in Q2, the positive long-term growth trajectory for Buvidal continued with sales during the quarter reaching 400 million SEK, a 31% increase versus the same period last year and 10% compared to the previous quarter. Strong performances were seen across all our major markets, notably in the UK, where funding continues to reach clinics and the criminal justice settings as anticipated. In Australia, we saw ordering patterns normalize after the recent changes in the reimbursement system, alongside continued growth in the long-acting buprenorphine segment, where we maintain an 80% share. Here, year-on-year growth was over 20%. In Germany, growth was also strong, notably in the community setting as a result of robust Salesforce execution and new market initiatives. France continues to make headway in the specialist center setting, and the French government recently acknowledged the utility of the long-acting injectable Buvidal, an orphan drug, with the release of additional funding for the coming year. And finally, in Spain, where it's growing. Buvidal is growing well. We have high and growing penetration in the segment and are seeing patient transfer now from methadone. At the end of the quarter, we estimate having well above 53,000 patients in treatment with Buvidal. We also continue to seek to expand the geographical reach for Buvidal, with reimbursement applications expected to finalize in Q3 and additional regulatory applications in progress. Moving to the US, considering the launch just nine months ago, the results for Q2 were impressive, with growing patient capture resulting in a continued positive picture for our royalty stream with revenue for the quarter of 45 million SEK, a 73% increase versus Q1. Braeburn has continued to execute on their plans. Payer support continues to improve, and recall that Brixadi's payer coverage after six months was already aligned with other long-acting medications in the US. The leading indicators are positive, including continuing high interest in medical education, high levels of prescription fill in all channels, and a broad and expanding fully functioning distribution network. This positive dynamics in execution is also resulting in high patient and healthcare professional satisfaction rates. The high adoption of Buvidal, alongside a significant unmet medical need and interest from patients and treatment providers, has reinforced our positive view of the market potential for this treatment in the US during the quarter. We also continue to grow and share the growing evidence base for both Buvidal and Brixadi. Key papers were published this quarter, with two in JAMA Network Open. The first indicates that Buvidal may be favorable to sublingual buprenorphine in reducing fentanyl use, and the second, from investigators at Yale University, highlighted the potential of weekly Buvidal to initiate treatment in patients presenting in the emergency room setting, for instance, after an overdose event, as it facilitates the transition to longer-term treatment. In Q2, we had a significant presence at many scientific congresses across our markets with presentations on the experience in patients with multiple psychiatric comorbidities, healthcare professionals' positive perspective on treatment, the long-acting group, and patient experiences from the start of treatment with Buvidal in France and treatment dynamics in Australia. Confirming the utility of different doses and the importance of a product with individualized and flexible dosing. On that point, I will hand back to Fredrik.

Fredrik Tiberg
10:49 - 21:12

Thank you, Richard. So, over to a quick R&D update. I will begin with a brief presentation on the top line. Final results from the 52-week phase three ANOVA two study, which was recently completed and announced yesterday. The study included a total of 135 participants on stable doses of standard of care at baseline. Of these, 81 were new patients in the trial, and 54 were rollover patients from 24 weeks of randomized treatment with CAM2029 or placebo in the ANOVA number one study. For placebo patients, we had two baselines: the standard of care baseline. So, entering the study on a standard of care and the placebo baseline after 24 weeks of receiving placebo, primary endpoints of the study were safety and tolerability over 52 weeks and secondary efficacy endpoints included. Changes from baseline in biochemical responses, symptom scores, quality of life, and patient and treatment satisfaction. Starting with the efficacy endpoints. Here are the response rates for insulin growth factor one (IGF-1), below or equal to one times the upper limit of normal after one year of treatment with CAM2029 versus the standard of care at baseline. Here, the standard of care is either a long-acting intramuscular, a cutaneous or a latrodect type depot, or 'autogel', as it's called in Europe, in newly studied patients mostly consisting of uncontrolled patients on stable doses of standard care. There was a significant increase in the response rate of 22.8% after switching to treatment with CAM2025 for 52 weeks. The improvement represented a key outcome of the Nova 2 study for rollover patients, who were generally biochemically controlled on stable doses of standard of care at the start of the study. These remained well controlled after switching to treatment with CAM2029 overall, also including placebo patients from occurring over one. There was an increase in the response rate of 12.7% from baseline to the end of treatment with CAM2029. If we look specifically at the placebo patients in the study, they were well controlled with high IGF-1 response rates at standard of care and remained controlled until the end of treatment with CAM2029. However, during the placebo period, a majority of these patients lost their biochemical response. Importantly, 68.5% of them regained response during treatment with CAM2029. These results support the long-term efficacy of CAM2029 in biochemically controlled and uncontrolled patients, as well as patients initiating treatment after brief interventions or post previous treatment episodes. Moving over to symptoms and looking at the full population. Remember, this includes the rollover patients who received a placebo during the first six months. As you can see in the graph, the symptom burden score estimated by the Acromegaly Index of Severity (AIS) score continuously improved on treatment with CAM2029 compared to standard of care at baseline. In addition to the improved AIS score, we also saw an increase in the number of patients who had no acromegaly symptoms after switching to CAM2029, with no recurrence or breakthrough symptoms at the end of the dosing intervals. So now, moving on to patient-reported outcomes, starting with quality of life. And as you can see in the figure here, there was a significant improvement in the recall, total, and psychological scores after switching to CAM2029. Note for the context here that these patients were all on stable doses of standard of care before switching. Continuing with patient-reported treatment satisfaction compared to standard of care at baseline. The graph on the left-hand side shows significant improvements in the validated Treatment Satisfaction Questionnaire for Medication (TSQM) convenience, effectiveness, and global satisfaction scores. The side effect score also numerically improved compared to standard of care. However, this effect was not statistically significant. Finally, on the right-hand side here, the patient satisfaction score clearly favored CAM2029, with the majority of patients rating the treatment as better than their previous one, and indeed, 56 patients rating it as much better. So finally, moving over to the safety of CAM2029, it was generally well tolerated with a safety profile consistent with the standard of care. Most adverse events were mild or moderate, grade 1 or 2 in intensity, with transient injection site reactions and gastrointestinal events being the most frequent observations. No severe adverse events related to CAM2029 were observed in the trial. One serious adverse event, a case of congestive heart failure of moderate intensity, was reported in a rollover placebo patient. However, this was resolved, and the patient continued treatment with CAM2029 throughout the trial. Two patients discontinued treatment due to adverse events, one case of mild depression, and one case of mild injection site reaction. Finally, no new safety signals were noted in adverse events, ECGs, or laboratory tests. In summary, we are very pleased with the Camurus topline results, demonstrating a safety profile consistent with standard of care and compelling data on biochemical and symptom control during the 52 weeks of treatment, alongside significant improvements in patient reported outcomes. Detailed results will be presented in an upcoming meeting or meetings and future publications. Of course, based on the combined scientific evidence from the Renovo program, we believe CAM2029, if approved, has the potential to become a new standard treatment for patients with acromegaly. Combining convenient, once-monthly self-administration with durable efficacy and, of course, a safety profile. We continue making good progress in the CAM2029 program across the treatment indications of acromegaly, castration-resistant pancreatic neuroendocrine tumors, and polycystic liver disease. And I'm looking forward to several key milestone events over the coming quarters, including the FDA approval decision in acromegaly by the date of 21st of October 2024, and a planned launch of Oclaiz™ in the US around the end of the year in GEP-NET or gastric pancreatic neuroendocrine tumors. We are expecting to finalize the core phase of the Sorrento study in H1 2025, and thereafter report topline results. This could allow for an NDA approval submission, I should say, to the FDA sometime in the second half of next year, and applications in other geographies to follow. So finally, topline results from the Positano study and PLD are expected early 2025. In advance of the planned US launch of Oclaiz™. We have been active, very active, in sharing scientific evidence from the Renovo program, and this has included several presentations, both oral and posters, at the leading endocrinology conferences ACC and Endo during the quarter. We also arranged a well-attended and appreciated satellite symposium about new emerging treatments of acromegaly, including CAM2029, at the EC in Stockholm in May. So, summing up the second quarter. I'm pleased with the continued strong performance of our teams commercially, as well as in development and the significant progress that we have made. During the quarter, Buvidal sales grew, and were enforced across the markets in the EU, MENA, and Australia because the uptake was also growing nicely in the US. Our pipeline continued to advance with significant events in terms of receiving MAA by EMA. And in parallel, we accelerated preparations for launch and the establishment of our US organization, and also advanced early pipeline programs, including the once-monthly semaglutide project. As a result of the solid performance to date, we reiterate our guidance and expect to finalize. As John said earlier, in the mid to high end of the previous interval. So, with that said, thank you everyone for listening. And now, please take over the call for the Q&A session.

Operator
21:13 - 21:26

Thanks, Frederick. If you'd like to ask a question, please dial the pound key and then a five on your telephone keypad. The first question comes from the line of Christopher Wood from SCB. Please go ahead.

Christopher Wood
21:30 - 21:31

Hi there. Can you hear me?

Fredrik Tiberg
21:32 - 21:35

Yes, we hear you very well, Christopher. Thank God.

Christopher Wood
21:35 - 22:03

Excellent. So, I guess I'd like to start by asking, in terms of Germany, some reimbursement reform was recently announced, and I wondered if that is the same as the reimbursement reform you had previously discussed. That was likely to have been delayed to, I guess it was, early next year. Could you comment on that, please?

Fredrik Tiberg
22:04 - 22:36

Yes, I can do that. I mean, these are different processes. So, the reimbursement reform is not specifically related to moving it all in any way. What we have been discussing is the change in the remuneration system, which is a separate process and is ongoing independently. And that is still targeted, I think, for the early part of next year. And.

Christopher Wood
22:36 - 22:40

You know what? Sorry.

Operator
22:40 - 22:40

No. Yeah.

Fredrik Tiberg
22:40 - 22:47

This is to do with the remuneration to doctors, not specifically the reimbursement of the product. Drug product. Right. Okay. Yeah. Thanks.

Christopher Wood
22:49 - 23:08

And do you know what it was that actually resulted in the delay specifically? And how confident are you? Because my understanding is that this has happened before. How confident are you that it will actually transpire in H1 2025?

Fredrik Tiberg
23:09 - 23:46

Well, no, we cannot say with certainty what level of confidence we have. What we understand is that all stakeholders in the process are positive and recognize that there is a need for a change. So we have a good understanding of that. And we know that there is a large interest here. And this is our best prediction. <trimmed>larity. Uh, what is nice, though, and I want to stress in this quarter, is, of course, that Germany, despite this change not having materialized yet, has been going very strongly.

Christopher Wood
23:49 - 24:14

Great. Thanks. Uh, and then, um, I guess I had a question on the gross margin for Google. It just seems to have been trending upward slightly over the past few quarters. Um, is this something we should expect to continue? And how high do you think it can get as you improve and get more leverage?

John Garay Alonso
24:15 - 25:21

Thanks a lot. Christopher. So, yes, you are correct. The gross margin for that has been increasing for the last four consecutive quarters, I think in Q2, if you do the calculation, it will be around 92.1%. And it's basically a combination of the volumes scaling up. So it's giving us economies of scale in the manufacturing process. And then we are finding more efficient ways to ship the product to the market. Can we assume that we will continue to grow in margins quarter on quarter? We are very prudent, and we think we are reaching the point at which the margin will remain there. We are already at 92%, and we improved it from a base of 88% last year. We have always been saying that we expect a margin in the range of 90%, perhaps 91%. So this is where we are at the moment, Christopher. But I don't think you can expect that the margin will continue growing or moving to 93%, 95% is not realistic.

Operator
25:21 - 25:21

Thank you.

Christopher Wood
25:25 - 25:56

The next question. Yeah. Sorry. May I ask a question on R&D? And sort of the cost cadence there? Firstly, should we still expect costs to move lower over the year? And secondly, I noticed you mentioned a new, long-acting formulation of Buvidal. Can you give us more details on that, please?

John Garay Alonso
25:57 - 26:34

So yes, our investment here to date. It is in the range of $350 million, and our full year guidance is in the range of $0.6 billion. It can be said that we are going to launch a new program of electric cars, announced in the interim report that the company is making the preparations to start a new clinical program in semaglutide. So we think that we are going to be in our market guidance in the range of $0.6 to $0.65 billion. Christopher, this is our guidance at the moment for R&D.

Fredrik Tiberg
26:35 - 27:05

With regards to the second question you have there, Christopher, about the longer-acting formulation, that is a development that is ongoing. We haven't given any indications on the status of this publicly. I would say that we don't expect it to affect our costs this year or our long-term costs, either. I mean, all of our internal developments currently are in the long-term plan.

Christopher Wood
27:08 - 27:33

Okay, thanks. And if I could just add one last question on R&D and then I'll turn it over. Would the interim that you mentioned in the report, for Sorrento, do you know, was it an interim where they looked at efficacy or did they look at futility? What can you comment about that?

Fredrik Tiberg
27:34 - 27:56

So I think that was a mistake. I did not mention an interim readout. I mean, we do have safety monitoring independently, but we are not conducting any futility analysis. So, yeah, we do not conduct any interim analysis on efficacy; that will come at the end.

Operator
27:56 - 27:58

Yes, thank you.

Unknown 1
28:01 - 28:02

The next question.

Operator
28:02 - 28:08

It's from Oscar Hough and Lam from Bryan Garnier. Please go ahead. Your line is open.

Christopher Wood
28:12 - 28:16

Yes, hi everyone. Thank you for taking my questions. And congrats on the congressional results. Regarding the topic previously discussed.

Karen
28:16 - 28:33

GLP-1 program, I was wondering when you plan on sharing pre-clential results. And as a follow-up question, maybe if you can already at this stage provide some granularity on the upcoming Phase 1 trial that you get towards the end of 2024 or start of 2025? First sentence.

Operator
28:34 - 28:34

Yeah.

Fredrik Tiberg
28:35 - 29:30

Thank you, Karen, for inquiring about the preclinical results. We have not included them in our plans for various reasons. Uh, at least not this year. In terms of the Phase I or Phase Ib clinical study, I think you can expect that to be very similar to other studies in the segment. Uh, having similar components, we have stated that it will be a dose-escalating study. Repeat those studies. But other than that, we will, of course, disclose the study as soon as the CTA is approved.

Karen
29:34 - 29:47

You're very clear. Thank you. And perhaps the second question, and I was wondering if you could provide some granularity on the number of patients that have been treated with Brixadi in the US. Um, perhaps you already said it before, but perhaps now. Mr.

Fredrik Tiberg
29:48 - 30:28

As this meeting is so close to the close of the quarter, we haven't provided any updates or received any that we could share with the market. There are estimates, including those by analysts here. And, we have the 7,000 patients that we reported last quarter and the growth. So, as we understand it, and from our partner, they are pleased with the continued uptake. Unfortunately, I cannot provide a precise figure at this point.

Karen
30:31 - 30:33

Okay.

Operator
30:35 - 30:51

As a reminder, if you wish to ask a question, please press the pound key five on your telephone keypad. You can have a brief pause just to see if there are any more questions coming in, and it doesn't seem that way. So, I hand the word back to you, Fredrik.

Fredrik Tiberg
30:53 - 31:11

Okay. Thank you so much. And thank you, everybody, for joining this call today. This was a very strong quarter for Camurus, and we look forward to providing the next update in the Q3 call in November. Thank you so much, and I wish you all the best for the summer.

Operator
31:11 - 31:13

We actually have one more question if we want to take it.

Fredrik Tiberg
31:14 - 31:15

Oh, of course, we'll take it.

Operator
31:15 - 31:19

It's from Patrick Lin from the NBA.

Fredrik Tiberg
31:20 - 31:21

Hello, Patrick.

Christopher Wood
31:24 - 31:25

Hi, guys.

Patrick Lin
31:25 - 31:40

Just a short one, and maybe two to you. Um, the tax rate in the quarter was a little bit higher than what I had expected. Uh, are there any changes in what we should expect going forward, or is this an anomaly, so to speak?

Operator
31:41 - 31:41

Um.

John Garay Alonso
31:41 - 32:10

No, it is the one we are expecting. I think we are in the range of 21.5%. If I remember correctly. Okay. Patrick. So it's aligned with us. What is happening is that we are starting to book taxes in the US for our operations. Q2 was the first quarter that we had, uh, ongoing operations in the US, and we have booked taxes for them as well. But no, not that I am aware of, nothing strange has happened in the quarter.

Operator
32:11 - 32:11

But.

Patrick Lin
32:13 - 32:24

Oh, okay. Because when I looked at it, I thought it was close to 29%. Now, for you to understand, And I was wondering if that was, uh, really recent.

John Garay Alonso
32:24 - 32:39

No, the catch up is what I'm saying. You see, the catch up of the US operations because we started a bit in Q1, but our effective tax reate is usually in the range of 21.5%. And we expect to be in that area.

Patrick Lin
32:41 - 32:42

Okay, great.

Fredrik Tiberg
32:42 - 32:43

So we are continuing.

Patrick Lin
32:43 - 32:44

Thank you, guys.

Fredrik Tiberg
32:44 - 32:44

Yeah.

Operator
32:44 - 32:45

Thank you.

Fredrik Tiberg
32:45 - 32:46

Super good.

Operator
32:49 - 32:53

Now there are no more questions. So I have the floor back again.

Fredrik Tiberg
32:54 - 33:03

Thank you, everybody. And it was, of course, a pleasure to give this call. And I'm looking forward to the next one in November. Thank, you. Have a great summer.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…